Business Wire

CLARIUS-MOBILE-HEALTH

17.1.2024 10:01:26 CET | Business Wire | Press release

Share
Clarius Receives CE Mark Certification for its Dual-Array Wireless Handheld Scanner for Whole-Body Ultrasound Imaging

Clarius Mobile Health, a global leader in wireless ultrasound solutions, has received CE Mark for its revolutionary Clarius PAL HD3 wireless handheld whole-body ultrasound scanner combining phased and linear arrays on a single head. It offers superior image quality of superficial and deep anatomy at the bedside1. The Clarius PAL HD3 high-definition wireless scanner is available today in Europe and the United Kingdom.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240117813694/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

New Clarius PAL HD3 wireless handheld whole-body ultrasound scanner uniquely combines phased and linear arrays on a single head. It offers superior image quality of superficial and deep anatomy at the bedside. CE-Certified, it's now available in Europe, the United Kingdom and the United States. (Graphic: Business Wire)

“You can probably do 95 to 99% of all the ultrasound imaging you need to do during a shift with this single device,” says Dr. Tom Cook who practices at a busy urban hospital. “If you compare the cost of this device to a cart-based system, you're talking a factor of 10 to 15, maybe even 20, depending on the type of system you're using. So, it's very, very inexpensive.”

Clarius is as compact as an iPhone and works seamlessly with iOS or Android devices, ensuring easy mobility from patient to patient. Clarius PAL HD3 is the only whole-body handheld scanner to deliver high-resolution images from the skin down to 40 cm of depth. Healthcare professionals can perform whole-body ultrasound exams without the need to swap devices or transport bulky systems between rooms. Clarius PAL HD3 is the 11th wireless handheld ultrasound scanner in the Clarius specialty ultrasound lineup.

“Our unique dual-array design was driven by our objective to deliver a portable whole-body ultrasound device that produces superior imaging quality, performance, and usability than what was currently available for clinicians,” says Kris Dickie, Chief Technology Officer at Clarius who led the project from ideation to commercialization. “Given the sales volume of the Clarius PAL since we introduced it in the United States late last year, we’re happy to confirm there’s definitely a strong market for a single, versatile device that supports multiple exams and broad clinical applications for hospital physicians.”

Clarius ultrasound scanners are proven to deliver superior image quality.1 Clarius uses the same advanced 8 beamformer processing technology used by higher-end traditional systems. This delivers up to 8 times the speed and performance of other handhelds for clear and detailed imaging to guide safe procedures and support precise and rapid assessments of patients at the bedside.

Watch this video to learn more about Clarius PAL HD3 from three emergency physicians.

1. Park KE, Mehta P, Tran C, Parikh AO, Zhou Q, Zhang-Nunes S. A comparison of five point-of-care ultrasound devices for use in ophthalmology and facial aesthetics. Ultrasound. 2023;0(0). doi:10.1177/1742271X231166895

About Clarius Mobile Health
Clarius is on a mission to make accurate, easy-to-use, and affordable ultrasound tools available to all medical professionals in every specialty. With decades of experience in medical imaging, the team knows that great ultrasound imaging improves confidence and patient care. Clarius handheld wireless ultrasound scanners connect to iOS and Android devices, delivering high-resolution ultrasound images traditionally only available with bulkier, high-end systems at a fraction of the cost.

Over four million high-definition scans have been performed using Clarius wireless handheld scanners. Clarius scanners are available in over 90 countries worldwide. Learn more at www.clarius.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240117813694/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release

Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (

Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release

Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,

BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release

The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu

Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release

Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo

Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release

Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets.​ “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.”​ Throughout his career, Dan has held senior leadership roles i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye